ClinicalTrials.gg
CompletedNCT06173570PURSUITUpdated Nov 17, 2025Results posted

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

A Phase 2 interventional study of AZD0780 and Placebo in Dyslipidemia, sponsored by AstraZeneca. Completed at 55 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
2nd of 11
428 · median 59
Started
2024
with 3 others
Phase 2
2 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 2nd largest by enrollment, is one of 4 that started in 2024, is one of 2 in phase 2, and was the 4th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.

03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Dyslipidemia,
  • Low-Density Lipoprotein Cholesterol
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, and females of non- 18 to 75 years of age, inclusive, at the time of signing the .
  • Participants with a fasting low-density lipoprotein cholesterol (LDL-C) higher than or equal to 70 mg/dL (1.8 mmol/L) and lower than 190 mg/dL (4.9 mmol/L) at screening.
  • Participants with fasting triglycerides lower than 400 mg/dL (lower than 4.52 mmol/L) at screening.
  • Should be receiving moderate or high-intensity statin therapy for more than or equal to 2 months prior to screening.
  • There should be no planned medication or dose change during study participation.
  • at or above 19.0 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • History or presence of gastrointestinal, hepatic or renal disease or any other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any uncontrolled or serious disease, or any medical (e.g., known major active infection or major hematological, renal, metabolic, gastrointestinal, respiratory, or endocrine dysfunction) or surgical condition that, in the opinion of the investigator, may either interfere with participation in the clinical study and/or put the participant at significant risk.
  • Poorly controlled type 2 diabetes mellitus, defined as (HbA1c) greater than 10 percent at screening.
  • Acute ischemic cardiovascular event in the last 12 months.
  • Heart failure with (NYHA) Class III-IV.
  • (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years.
  • Recipient of any major organ transplant, e.g., lung, liver, heart, bone marrow, renal.
  • LDL or plasma apheresis within 12 months prior to randomization.
  • Uncontrolled hypertension.
  • Any abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12 lead ECG as judged by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
428 participants (actual)

Study arms

  • Experimental
    Arm A

    AZD0780, Dose 1

    Drug: AZD0780

  • Experimental
    Arm B

    AZD0780, Dose 2

    Drug: AZD0780

  • Experimental
    Arm C

    AZD0780, Dose 3

    Drug: AZD0780

  • Experimental
    Arm D

    AZD0780, Dose 4

    Drug: AZD0780

  • Placebo comparator
    Arm E

    Placebo, matched for appearance

    Drug: Placebo

Interventions

  • AZD0780 administered orally, once daily for 12 weeks

  • DrugPlacebo

    Placebo administered orally, once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12

    Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

Secondary outcomes

  1. Percent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  2. Percent Change From Baseline of Total Cholesterol at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  3. Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  4. Percent Change From Baseline of Triglycerides at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  5. Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  6. Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  7. Percent Change From Baseline of Apolipoprotein A1 at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  8. Percent Change From Baseline of Apolipoprotein B at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

    Time frame: From first day of treatment up to week 12

  9. Percent Change From Baseline of Total Cholesterol at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  10. Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  11. Percent Change From Baseline of Triglycerides at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  12. Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  13. Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  14. Percent Change From Baseline of Apolipoprotein A1 at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  15. Percent Change From Baseline of Apolipoprotein B at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

    Time frame: From first day of treatment up to week 12

  16. Percent Change From Baseline of Lipoprotein-a at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

    Time frame: From first day of treatment up to week 12

  17. Percent Change From Baseline of Remnant Cholesterol at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

    Time frame: From first day of treatment up to week 12

  18. Percent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 12

    Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

    Time frame: From first day of treatment up to week 12

  19. AZD0780 Plasma Concentrations Summarized by Sampling Timepoint

    Geometric mean plasma concentration; LLOQ = 0.01 umol/L; BLQ values are handled as Not Quantified (NQ)

    Time frame: From week 1 up to week 12

07

Results

Posted Nov 17, 2025
Limitations and caveats
The secondary endpoints - percent change from baseline in Lipoprotein-a, remnant cholesterol, and hsCRP at Week 12 - could not be reliably interpreted using the planned inferential statistics model due to individual unexpected values and skewed data. Therefore, the endpoint analyses use descriptive statistics to illustrate the data distribution for these parameters.

Participant flow

The study was conducted from January 2024 to September 2024 in 55 research sites in 8 countries (United States, Canada, Czech Republic, Denmark, Hungary, Japan, Slovakia, and Spain).

Participant flow — Overall Study
MilestoneAZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Started8685858587
Started treatment8685848586
Completed8181848082
Not completed54155
Withdrew: Adverse event10020
Withdrew: Lost to follow-up10002
Withdrew: Protocol violation02001
Withdrew: Withdrawal by subject01111
Withdrew: Non-compliance with study drug10000
Withdrew: Screen failure00001
Withdrew: Other21020

Outcome measures

PrimaryPercent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12

Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12-31.19 (-37.06 to -25.32)-33.83 (-39.78 to -27.88)-41.09 (-46.92 to -35.25)-46.62 (-52.48 to -40.76)4.08 (-1.84 to 10.00)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -35.27 · 95% CI -43.61 to -26.93Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -37.91 · 95% CI -46.31 to -29.51Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -45.17 · 95% CI -53.47 to -36.86Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -50.70 · 95% CI -59.03 to -42.37Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-30.47 (-36.45 to -24.49)-33.35 (-39.44 to -27.26)-40.47 (-46.42 to -34.53)-46.41 (-52.48 to -40.35)3.39 (-2.63 to 9.40)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -33.85 · 95% CI -42.34 to -25.37Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -36.73 · 95% CI -45.30 to -28.17Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -43.86 · 95% CI -52.31 to -35.41Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -49.80 · 95% CI -58.35 to -41.25Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Total Cholesterol at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Total Cholesterol at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Total Cholesterol at Week 12-18.93 (-22.48 to -15.38)-20.09 (-23.70 to -16.48)-24.84 (-28.36 to -21.32)-27.06 (-30.62 to -23.51)2.29 (-1.29 to 5.88)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -21.22 · 95% CI -26.27 to -16.18Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -22.39 · 95% CI -27.48 to -17.30Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -27.14 · 95% CI -32.16 to -22.11Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -29.36 · 95% CI -34.40 to -24.31Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 120.12 (-2.96 to 3.19)4.03 (0.93 to 7.12)1.97 (-1.07 to 5.00)4.66 (1.60 to 7.72)3.65 (0.58 to 6.71)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.111 · Mean difference (net): -3.53 · 95% CI -7.87 to 0.81Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.864 · Mean difference (net): 0.38 · 95% CI -3.98 to 4.74Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.445 · Mean difference (net): -1.68 · 95% CI -5.99 to 2.63Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.648 · Mean difference (net): 1.01 · 95% CI -3.32 to 5.34Difference = AZD0780 - Placebo; positive values favor AZD0780.
SecondaryPercent Change From Baseline of Triglycerides at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Triglycerides at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Triglycerides at Week 123.06 (-5.05 to 11.17)2.90 (-5.29 to 11.08)1.93 (-5.99 to 9.85)-0.44 (-8.52 to 7.63)9.56 (1.47 to 17.65)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.266 · Mean difference (net): -6.50 · 95% CI -17.97 to 4.96Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.256 · Mean difference (net): -6.67 · 95% CI -18.17 to 4.84Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.186 · Mean difference (net): -7.63 · 95% CI -18.95 to 3.69Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.086 · Mean difference (net): -10.00 · 95% CI -21.44 to 1.43Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12-26.85 (-32.65 to -21.04)-29.86 (-35.75 to -23.97)-35.13 (-40.92 to -29.35)-41.65 (-47.45 to -35.85)3.53 (-2.33 to 9.39)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -30.38 · 95% CI -38.63 to -22.12Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -33.39 · 95% CI -41.71 to -25.08Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -38.66 · 95% CI -46.90 to -30.43Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -45.18 · 95% CI -53.43 to -36.94Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 121.13 (-6.55 to 8.81)4.02 (-3.69 to 11.73)2.21 (-5.26 to 9.68)0.46 (-7.15 to 8.07)7.19 (-0.52 to 14.90)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.276 · Mean difference (net): -6.06 · 95% CI -16.96 to 4.84Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.568 · Mean difference (net): -3.17 · 95% CI -14.08 to 7.73Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.363 · Mean difference (net): -4.98 · 95% CI -15.71 to 5.75Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.223 · Mean difference (net): -6.73 · 95% CI -17.57 to 4.11Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Apolipoprotein A1 at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Apolipoprotein A1 at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Apolipoprotein A1 at Week 121.67 (-1.00 to 4.34)3.25 (0.58 to 5.93)3.61 (1.02 to 6.21)5.72 (3.08 to 8.36)4.46 (1.80 to 7.12)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.146 · Mean difference (net): -2.79 · 95% CI -6.56 to 0.98Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.530 · Mean difference (net): -1.21 · 95% CI -4.98 to 2.56Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.654 · Mean difference (net): -0.85 · 95% CI -4.56 to 2.87Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.509 · Mean difference (net): 1.26 · 95% CI -2.48 to 5.00Difference = AZD0780 - Placebo; positive values favor AZD0780.
SecondaryPercent Change From Baseline of Apolipoprotein B at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Apolipoprotein B at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Apolipoprotein B at Week 12-24.08 (-28.37 to -19.80)-25.39 (-29.71 to -21.07)-34.33 (-38.53 to -30.12)-36.95 (-41.20 to -32.71)2.92 (-1.39 to 7.23)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -27.00 · 95% CI -33.08 to -20.93Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -28.31 · 95% CI -34.42 to -22.20Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -37.25 · 95% CI -43.27 to -31.23Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -39.87 · 95% CI -45.92 to -33.83Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Total Cholesterol at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Total Cholesterol at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Total Cholesterol at Week 12-18.23 (-21.88 to -14.58)-19.80 (-23.54 to -16.07)-24.54 (-28.14 to -20.94)-26.90 (-30.60 to -23.20)1.73 (-1.88 to 5.34)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -19.96 · 95% CI -25.09 to -14.84Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -21.54 · 95% CI -26.73 to -16.35Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -26.27 · 95% CI -31.37 to -21.18Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = < 0.001 · Mean difference (net): -28.64 · 95% CI -33.80 to -23.48Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 120.80 (-2.29 to 3.89)3.66 (0.58 to 6.75)2.17 (-0.85 to 5.19)4.65 (1.61 to 7.70)3.11 (0.11 to 6.12)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.292 · Mean difference (net): -2.31 · 95% CI -6.62 to 1.99Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.802 · Mean difference (net): 0.55 · 95% CI -3.76 to 4.86Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.664 · Mean difference (net): -0.94 · 95% CI -5.21 to 3.32Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.481 · Mean difference (net): 1.54 · 95% CI -2.74 to 5.82Difference = AZD0780 - Placebo; positive values favor AZD0780.
SecondaryPercent Change From Baseline of Triglycerides at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Triglycerides at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Triglycerides at Week 122.81 (-5.25 to 10.86)2.17 (-5.93 to 10.28)1.72 (-6.09 to 9.54)-0.83 (-8.87 to 7.22)9.04 (1.16 to 16.92)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.278 · Mean difference (net): -6.23 · 95% CI -17.50 to 5.03Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.234 · Mean difference (net): -6.87 · 95% CI -18.19 to 4.45Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.196 · Mean difference (net): -7.32 · 95% CI -18.41 to 3.78Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.086 · Mean difference (net): -9.87 · 95% CI -21.14 to 1.41Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12-26.13 (-31.94 to -20.32)-29.42 (-35.34 to -23.49)-34.77 (-40.59 to -28.95)-41.35 (-47.27 to -35.43)2.86 (-2.91 to 8.62)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -28.99 · 95% CI -37.16 to -20.81Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -32.28 · 95% CI -40.54 to -24.02Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -37.63 · 95% CI -45.82 to -29.44Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -44.21 · 95% CI -52.47 to -35.94Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 120.81 (-6.81 to 8.43)2.67 (-4.91 to 10.26)1.77 (-5.59 to 9.13)0.42 (-7.18 to 8.02)6.74 (-0.68 to 14.15)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.275 · Mean difference (net): -5.93 · 95% CI -16.57 to 4.71Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.451 · Mean difference (net): -4.06 · 95% CI -14.63 to 6.51Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.351 · Mean difference (net): -4.97 · 95% CI -15.41 to 5.47Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.243 · Mean difference (net): -6.32 · 95% CI -16.92 to 4.29Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Apolipoprotein A1 at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Apolipoprotein A1 at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Apolipoprotein A1 at Week 122.52 (-0.18 to 5.22)2.89 (0.14 to 5.64)3.79 (1.19 to 6.39)5.55 (2.88 to 8.22)3.82 (1.15 to 6.48)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = 0.501 · Mean difference (net): -1.30 · 95% CI -5.08 to 2.48Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = 0.634 · Mean difference (net): -0.93 · 95% CI -4.74 to 2.89Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = 0.990 · Mean difference (net): -0.02 · 95% CI -3.74 to 3.70Difference = AZD0780 - Placebo; positive values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = 0.366 · Mean difference (net): 1.73 · 95% CI -2.03 to 5.50Difference = AZD0780 - Placebo; positive values favor AZD0780.
SecondaryPercent Change From Baseline of Apolipoprotein B at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.

Time frame:
From first day of treatment up to week 12
Reported as:
Least squares mean · Percent Change (%)
Percent Change From Baseline of Apolipoprotein B at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Apolipoprotein B at Week 12-23.35 (-27.79 to -18.91)-24.53 (-29.06 to -19.99)-33.85 (-38.18 to -29.51)-36.86 (-41.35 to -32.37)2.44 (-2.00 to 6.89)
Statistical analysis
  • AZD0780 1 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -25.79 · 95% CI -32.08 to -19.51Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 3 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -26.97 · 95% CI -33.33 to -20.62Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 10 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -36.29 · 95% CI -42.50 to -30.08Difference = AZD0780 - Placebo; negative values favor AZD0780.
  • AZD0780 30 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -39.30 · 95% CI -45.61 to -32.99Difference = AZD0780 - Placebo; negative values favor AZD0780.
SecondaryPercent Change From Baseline of Lipoprotein-a at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

Time frame:
From first day of treatment up to week 12
Reported as:
Median · Percent Change (%)
Percent Change From Baseline of Lipoprotein-a at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Lipoprotein-a at Week 12-7.48 (-64.6 to 319.6)-11.16 (-56.7 to 2582.3)-19.57 (-66.3 to 36.6)-19.43 (-71.3 to 55.6)0.00 (-46.3 to 98.9)
SecondaryPercent Change From Baseline of Remnant Cholesterol at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

Time frame:
From first day of treatment up to week 12
Reported as:
Median · Percent Change (%)
Percent Change From Baseline of Remnant Cholesterol at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of Remnant Cholesterol at Week 12-9.09 (-77.8 to 160.0)-8.33 (-169.7 to 671.4)-22.95 (-1200.0 to 266.7)-18.31 (-200.0 to 420.0)-5.00 (-85.7 to 558.3)
SecondaryPercent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 12

Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.

Time frame:
From first day of treatment up to week 12
Reported as:
Median · Percent Change (%)
Percent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 12
Percent Change (%)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
Percent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 120.00 (-96.8 to 2500.0)0.00 (-79.8 to 716.7)0.00 (-98.1 to 4950.0)-22.22 (-93.3 to 2603.0)0.00 (-75.7 to 1358.3)
SecondaryAZD0780 Plasma Concentrations Summarized by Sampling Timepoint

Geometric mean plasma concentration; LLOQ = 0.01 umol/L; BLQ values are handled as Not Quantified (NQ)

Time frame:
From week 1 up to week 12
Reported as:
Geometric mean · umol/L
AZD0780 Plasma Concentrations Summarized by Sampling Timepoint
umol/LAZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mg
Week 10.0790 ± 76.76030.2523 ± 54.04630.8120 ± 72.60512.6420 ± 58.0213
Week 20.0926 ± 71.74850.2639 ± 75.68040.8156 ± 95.15452.6676 ± 55.8538
Week 40.0901 ± 81.29700.2380 ± 98.84480.8393 ± 74.66362.7059 ± 47.5671
Week 80.0932 ± 68.62700.2359 ± 102.53510.8350 ± 92.96402.4911 ± 102.6420
Week 120.0957 ± 61.85730.2317 ± 111.26360.7221 ± 119.94362.4373 ± 134.1014

Adverse events

Collected over Adverse events were collected from start of study treatment, throughout the 12-week treatment period, and the 2-weeks follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD0780 1 mg0/86 (0%)2/86 (2.3%)4/86 (4.7%)
AZD0780 3 mg0/85 (0%)2/85 (2.4%)2/85 (2.4%)
AZD0780 10 mg0/84 (0%)2/84 (2.4%)2/84 (2.4%)
AZD0780 30 mg0/85 (0%)1/85 (1.2%)3/85 (3.5%)
Placebo0/86 (0%)0/86 (0%)5/86 (5.8%)
Most frequent serious events
Most frequent serious events
EventAZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
OsteomyelitisInfections and infestations0/860/851/840/850/86
Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/860/851/840/850/86
Colonic abscessInfections and infestations0/861/850/840/850/86
Transient ischaemic attackNervous system disorders0/860/850/841/850/86
Inguinal herniaGastrointestinal disorders0/861/850/840/850/86
Major DepressionPsychiatric disorders1/860/850/840/850/86
SyncopeNervous system disorders1/860/850/840/850/86
Angina pectorisCardiac disorders1/860/850/840/850/86
Most frequent other events
Most frequent other events
EventAZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlacebo
HypertensionVascular disorders4/862/852/843/855/86

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
<=18 years000000
Between 18 and 65 years4759395047242
>=65 years3926453539184
Age, Continuous
Age, Continuous(Years)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
Mean62.7 ± 7.960.9 ± 7.263.9 ± 7.262.3 ± 7.962.3 ± 7.862.4 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
Female4141374144204
Male4544474442222
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
Hispanic or Latino510612841
Not Hispanic or Latino8175787378385
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
American Indian or Alaska Native010001
Asian8666632
Native Hawaiian or Other Pacific Islander000000
Black or African American5344622
White7375737473368
More than one race000011
Unknown or Not Reported001102
Low-Density Lipoprotein Cholesterol (LDL-C)
Low-Density Lipoprotein Cholesterol (LDL-C)(mmol/L)AZD0780 1 mgAZD0780 3 mgAZD0780 10 mgAZD0780 30 mgPlaceboTotal
Mean2.6822 ± 0.69182.7258 ± 0.89602.4784 ± 0.71222.5500 ± 0.69392.5769 ± 0.66202.6031 ± 0.7378
08

Study locations

55 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Santa Ana, California 92704, United States
  • Research Site
    Boca Raton, Florida 33434, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Inverness, Florida 34452, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Louisville, Kentucky 40213, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    San Marcos, Texas 78666, United States
  • Research Site
    Barrie, Ontario L4N 7L3, Canada
  • Research Site
    Brampton, Ontario L6S 0C6, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Concord, Ontario L4K 4M2, Canada
  • Research Site
    Guelph, Ontario N1H 1B1, Canada
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
  • Research Site
    Benešov, 256 01, Czechia
  • Research Site
    Brandýs nad Labem, 250 01, Czechia
  • Research Site
    Brno, 603 00, Czechia
  • Research Site
    Louny, 440 01, Czechia
  • Research Site
    Náchod, 547 01, Czechia
  • Research Site
    Prague, 150 00, Czechia
  • Research Site
    Příbram, 261 01, Czechia
  • Research Site
    Teplice, 415 01, Czechia
  • Research Site
    Uherské Hradiště, 68601, Czechia
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Herning, 7400, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Svendborg, 5700, Denmark
  • Research Site
    Viborg, 8800, Denmark
  • Research Site
    Budapest, 1027, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Orosháza, 5900, Hungary
  • Research Site
    Pécs, 7624, Hungary
  • Research Site
    Chūōku, 103-0027, Japan
  • Research Site
    Itabashi-ku, 173-0004, Japan
  • Research Site
    Bratislava, 831 03, Slovakia
  • Research Site
    Brezno, 977 01, Slovakia
  • Research Site
    Lučenec, 984 01, Slovakia
  • Research Site
    Prešov, 080 01, Slovakia
  • Research Site
    Rožňava, 048 01, Slovakia
  • Research Site
    Svidník, 08901, Slovakia
  • Research Site
    Trebišov, 075 01, Slovakia
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Ferrol, 15405, Spain
  • Research Site
    Santiago(A Coruña), 15706, Spain
  • Research Site
    Seville, 41004, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Seville, 41071, Spain
09

References and documents

Publications

  • Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, Wallerstedt E, Carter D, Middlemiss J, Twaddle L, McCarthy MC, Rosenmeier JB. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025 Jun 3;85(21):1996-2007. doi: 10.1016/j.jacc.2025.03.499. Epub 2025 Mar 31. PubMed 40167413 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2024, 8 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 15, 2023
StartActual
Jan 19, 2024
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Results first posted
Nov 17, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06173570
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 19, 2024
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Results posted
Nov 17, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion